All In Biotech

Drug Trial Radar · NCT05915728

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

410

Actual

Start

Jul 24, 2023

Primary completion

May 31, 2024

Study completion Jun 1, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI). MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject contrast agent into a patient's vein to perform a so called "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve the evaluation. The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd). Gadoquatrane is a new contrast agent under development with a lower amount of Gd needed per CE-MRI. The main purpose of this study is to learn whether CE-MRI scans with gadoquatrane work better than MRI scans without the use of a contrast agent (GBCA). The researchers will compare the ability to detect known or suspected problems (except brain or spinal cord-related problems) with gadoquatrane-MRI scans to plain-MRI scans without the use of a contrast agent. The participants will undergo 2 MRI scans, one with gadoquatrane and one with currently used GBCA. Both contrast agents will be injected into the vein. Each participant will be in the study for between 6 and 42 days with up to 7 doctor visits. At the start or during the study, the doctors and their study team will: * take blood and urine samples * do physical examinations * check blood pressure and heart rate * review the MRI scans obtained in the study and decide on the diagnosis * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

Conditions

  • Contrast Enhancement in Magnetic Resonance Imaging
  • Non-central Nervous System Pathology

Interventions

  • Gadoquatrane (BAY1747846)Drug

    0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose

  • GadobutrolDrug

    Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

  • Gadoterate meglumineDrug

    Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

  • GadoteridolDrug

    Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visualization Parameter Contrast Enhancement Assessed by Separate Blinded Evaluation of Unenhanced and Combined Pre- and Post-gadoquatrane MRI, by a BICRTime frame: 1 day procedure
  2. Visualization Parameter Delineation Assessed by Separate Blinded Evaluation of Unenhanced and Combined Pre- and Post-gadoquatrane MRI, by a BICRTime frame: 1 day procedure
  3. Visualization Parameter Morphology Assessed by Separate Blinded Evaluation of Unenhanced and Combined Pre- and Post-gadoquatrane MRI, by a BICRTime frame: 1 day procedure

Locations

85 sites in 16 countries. Site status is shown where the registry gives one.

  • UAB Hospital - Radiology

    Birmingham, Alabama

  • Halo Diagnostics - Indian Wells

    Indian Wells, California

  • UC Irvine Medical Center

    Orange, California

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Biogenix Molecular, LLC

    Miami, Florida

  • University of Missouri Hospital and Clinic - Neuroradiology

    Columbia, Missouri

  • Duke University School of Medicine - Early Phase Research Unit - Neurology

    Durham, North Carolina

  • Pennsylvania State University College of Medicine

    Hershey, Pennsylvania

  • Houston Methodist Hospital - Cardiology

    Houston, Texas

  • Fundacion Cientifica del Sur | Centro de Lomas de Zamora - Imaging Interventionism Department

    Lomas de Zamora, Buenos Aires, Buenos Aires, Argentina

  • Instituto Alexander Fleming | Sede Central - Departamento de Diagnostico por Imagenes

    CABA, Ciudad Auton. de Buenos Aires, Argentina

  • Sanatorio Otamendi | Imaging Diagnostic Center

    Ciudad Autonoma de Buenos Aire, Ciudad Auton. de Buenos Aires, Argentina

  • Centro de Diagnostico Enrique Rossi | Departamento de Investigacion Clínica

    Ciudad Autonoma de Buenos Aire, Ciudad Auton. de Buenos Aires, Argentina

  • Sanatorio Allende | Departamento de Investigación Clínica

    Córdoba, Córdoba Province, Argentina

  • Clinica Universitaria Reina Fabiola | Consultorios Externos

    Córdoba, Córdoba Province, Argentina

  • Acibadem City Clinic | University Multiprofile Hospital for Active Treatment Tokuda - Radiology Department

    Sofia, Bulgaria

  • University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Radiology Department

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment Dr Georgi Stranski Pleven | Surgery Department

    Pleven, Pleven Province, Bulgaria

  • Multiprofile Hospital for Active Treatment Central Onco Hospital | Independent Medical Diagnostic Laboratory Mediscan

    Plovdiv, Plovdiv Province, Bulgaria

  • University Multiprofile Hospital for Active Treatment Sveti Georgi | Base II - Imaging Diagnostic Department

    Plovdiv, Plovdiv Province, Bulgaria

  • University Multiprofile Hospital For Active Treatment 'Alexandrovska' EAD

    Sofia, Sofia City Province, Bulgaria

  • University Multiprofile Hospital for Active Treatment 'Sveta Ekaterina' EAD

    Sofia, Sofia City Province, Bulgaria

  • University Multiprofile Hospital for Active Treatment St. Ivan Rilski | Radiology Department

    Sofia, Sofia City Province, Bulgaria

  • Hôpital du Sacré-Cœur de Montréal | Radiology

    Montreal, Quebec, Canada

  • Beijing Chaoyang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University First Hospital - Oncology Department

    Beijing, Beijing Municipality, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • Huai'an First People's Hospital, Nanjing Medical University

    Huai'an, Jiangsu, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • Fakultní nemocnice Ostrava - Radiodiagnostický ústav

    Ostrava, Czechia

  • Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice

    Pardubice, Czechia

  • Fakultni nemocnice Plzen - Lochotin

    Pilsen, Czechia

  • Všeobecná fakultní nemocnice v Praze

    Prague, Czechia

  • Fakultní Thomayerova nemocnice - klinicko-farmakologická jednotka

    Praha 4 - Krc, Czechia

  • Fakultní nemocnice Brno - Klinika radiologie a nukleární medicíny

    Brno, South Moravian, Czechia

  • Centre Hospitalier Universitaire de Dijon

    Dijon, France

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.